Literature DB >> 15750082

Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.

M Raquel Marín Jiménez1, Juan Luis Muñoz Bellido, José Angel García Rodríguez.   

Abstract

We developed a case-control study in order to identify risk factors associated with pharyngeal colonization by Streptococcus pneumoniae with reduced susceptibility to fluoroquinolones (ciprofloxacin MIC, > or =4 microg/ml). A total of 400 patients were studied for colonization by quinolone-nonsusceptible S. pneumoniae (QNSP) isolates and risk factors for this colonization. Isolate susceptibility was determined by the agar dilution method. Forty patients were colonized by QNSP (case patients), and 360 patients were not colonized by QNSP (control patients). The MIC range of ciprofloxacin for QNSP isolates was 4 to 8 microg/ml. No isolates were resistant to levofloxacin and moxifloxacin. Risk factors significantly associated with QNSP colonization, according to univariate analysis, were recent hospitalizations (odds ratio [OR], 3.43; 95% confidence interval [CI], 1.6 to 7.2; P < 0.01) and prior exposure to fluoroquinolones (OR, 6.04; 95% CI, 3.0 to 12.0; P < 0.01). Other factors such as chronic obstructive pulmonary disease (OR, 1.94; 95% CI; 0.7 to 5.0), prior exposure to penicillins (OR, 1,68; 95% CI, 0.8 to 3.3) and prior exposure to macrolides (OR 2; 95% CI, 0.6 to 6.2) were more frequent among patients colonized with QNSP, but there was no statistical significance. Multivariate analysis showed that exposure to fluoroquinolones was the only independent factor associated with colonization by QNSP (OR, 4.2; 95% CI, 1.8 to 9.4; P < 0.01). Throat colonization by QNSP is becoming frequent, though most of these isolates (all the isolates in this case) remain susceptible to newer fluoroquinolones. Previous treatment with fluoroquinolones seems to be the main risk factor associated with colonization by QNSP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750082      PMCID: PMC1081248          DOI: 10.1128/JCM.43.5.1193-1197.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.

Authors:  P L Ho; T L Que; D N Tsang; T K Ng; K H Chow; W H Seto
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.

Authors:  Javier Aspa; Olga Rajas; Felipe Rodríguez de Castro; José Blanquer; Rafael Zalacain; Asunción Fenoll; Rosa de Celis; Antonio Vargas; Francisco Rodríguez Salvanés; Pedro Pablo España; Jordi Rello; Antoni Torres
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

3.  Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

Authors:  C E Goldsmith; J E Moore; P G Murphy; J E Ambler
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

4.  Role of infection in chronic bronchitis.

Authors:  D W Gump; C A Phillips; B R Forsyth; K McIntosh; K R Lamborn; W H Stouch
Journal:  Am Rev Respir Dis       Date:  1976-04

Review 5.  The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones.

Authors:  Roman Pallares; Asuncion Fenoll; Josefina Liñares
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

6.  DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

Authors:  Michael R Jacobs; David Felmingham; Peter C Appelbaum; Reuben N Grüneberg
Journal:  J Antimicrob Chemother       Date:  2003-07-15       Impact factor: 5.790

8.  Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.

Authors:  María-Isabel Morosini; Elena Loza; Rosa del Campo; Felisa Almaraz; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.

Authors:  Adela G de la Campa; Luz Balsalobre; Carmen Ardanuy; Asunción Fenoll; Emilio Pérez-Trallero; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

10.  Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.

Authors:  Sue Lim; Darrin Bast; Allison McGeer; Joyce de Azavedo; Donald E Low
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  5 in total

Review 1.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

2.  Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae.

Authors:  Cheol-In Kang; Jin Yang Baek; Kyeongman Jeon; So Hyun Kim; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

Review 3.  Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

Authors:  Benjamin J Epstein; John G Gums
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; T M So; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-06       Impact factor: 3.267

5.  In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.

Authors:  Kazuki Hoshino; Kazue Inoue; Yoichi Murakami; Yuichi Kurosaka; Kenji Namba; Yoshinori Kashimoto; Saori Uoyama; Ryo Okumura; Saito Higuchi; Tsuyoshi Otani
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.